Valuation: Virbac

Market Cap 3B 3.36B 2.76B 2.51B 4.75B 315B 4.87B 33.03B 13.16B 169B 12.62B 12.35B 531B P/E 2026 *
17.3x
P/E 2027 * 15.6x
Enterprise Value 3.11B 3.48B 2.86B 2.6B 4.92B 326B 5.04B 34.22B 13.64B 175B 13.07B 12.79B 550B EV / Sales 2026 *
2x
EV / Sales 2027 * 1.86x
Free-Float
49.03%
Yield 2026 *
0.47%
Yield 2027 * 0.53%
1 day-0.42%
1 week+0.56%
Current month+2.74%
1 month+12.46%
3 months+6.74%
6 months+1.28%
Current year-0.28%
1 week 347
Extreme 347
366
1 month 316
Extreme 316
366
Current year 297
Extreme 297
389.5
1 year 297
Extreme 297
389.5
3 years 249.7
Extreme 249.7
400
5 years 215
Extreme 215
446.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Date Insider Type Main position Quantity % Market Cap. Importance
4/22/24 A Sell

Chief Executive Officer

810 0.0096%
4/22/24 A Sell

Chief Executive Officer

140 0.0017%
4/22/24 A Sell

Chief Executive Officer

1,688 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%+0.56%+3.18%+30.59% 3.36B
+4.28%+0.07%+52.75%+138.78% 1,258B
+2.13%+4.27%+51.21%+91.36% 679B
+0.68%+1.54%+33.83%+112.47% 518B
-0.17%+2.17%+43.24%+68.74% 390B
+1.38%+0.27%+72.42%+45.30% 367B
+0.37%+1.83%+31.02%+59.67% 307B
-0.58%+1.67%+6.58%+38.65% 293B
+1.04%-0.05%+45.29%+76.18% 252B
+1.46%-0.59%+42.48%+125.82% 210B
Average +0.39%+1.06%+38.20%+78.76% 428B
Weighted average by Cap. +0.49%+1.18%+45.33%+96.72%

Financials

2026 *2027 *
Net sales 1.56B 1.74B 1.43B 1.3B 2.46B 163B 2.52B 17.12B 6.82B 87.43B 6.54B 6.4B 275B 1.65B 1.85B 1.52B 1.38B 2.61B 173B 2.68B 18.17B 7.24B 92.81B 6.94B 6.79B 292B
Net income 173M 194M 159M 145M 274M 18.18B 281M 1.91B 760M 9.73B 728M 713M 30.66B 193M 216M 177M 161M 305M 20.25B 313M 2.12B 846M 10.84B 811M 794M 34.15B
Net Debt 108M 121M 99.61M 90.4M 171M 11.37B 176M 1.19B 475M 6.09B 455M 445M 19.17B 64.2M 71.92M 59.08M 53.62M 102M 6.74B 104M 707M 282M 3.61B 270M 264M 11.37B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
10/11/26 €356.50 -0.42% 274
09/11/26 €358.00 -0.42% 3,067
06/11/26 €359.50 0.00% 3,366
05/11/26 €359.50 -0.14% 11,244
04/11/26 €360.00 +1.55% 6,630
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
358.00EUR
Average target price
412.29EUR
Spread / Average Target
+15.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac
  1. Stock Market
  2. Stocks
  3. VIRP Stock